Title:

Advances in epidemiological methods and utilisation of large databases: A methodological review of observational studies on central nervous system drugs use in pregnancy and central nervous system outcomes in children

Authors:

Zixuan Wang[1], Phoebe WH Ho[2], Michael TH Choy[2], Ian CK Wong[1,2], Ruth Brauer[1] and Kenneth KC Man[1-3]

Authors affiliations:

[1]Research Department of Practice and Policy, UCL School of Pharmacy, London, United Kingdom

[2]Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong

[3]Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands

Running heading:

Methodological review of CNS drug use in pregnancy and outcomes in children

Correspondence to: Kenneth KC Man, Research Department of Practice and Policy, UCL School of Pharmacy, Mezzanine Floor, BMA House, Entrance A, Tavistock Square, London WC1H 9JP London, United Kingdom.

Tel: +44 7426956973

Email: kenneth.man@ucl.ac.uk

Abstract (279 words)

Introduction: Studies have used various epidemiological approaches to study the association between central nervous system (CNS) drugs use in pregnancy and CNS outcomes in children. Clinical adverse effects were generally focused on, while, variations in methodologies were not given sufficient attention.

Objective: To review the methodological characteristics of existing studies in order to identify any limitations and recommend further research.

Methods: A systematic literature search was conducted on observational studies listed in PubMed from 1 January 1946 to 21 September 2017. Following independent screening and data extraction, a review addressing the trends of relevant studies, differences between various data sources, methods used to address bias and confounders, and conduct statistical analyses was undertaken.

Results: 111 observational studies, 25 case-control studies, and 86 cohort studies were included in the review. Publications dating from 1978 to 2006 mainly focussed on antiepileptic drugs, but research on antidepressants has increased from 2007 onwards. Only one study focussed on antipsychotic use during pregnancy was identified. 46 studies obtained data from an administrative database/registry, 20 from ad hoc disease registries, and 41 from ad hoc clinical samples. Most studies (58%) adjusted the confounding factors using general adjustment, while only a few studies used advanced methods such as sibling-matched models and the propensity score methods. 42 articles used univariate analyses and 69 conducted multivariable regression analyses.

Conclusion: Multiple factors, such as different study designs and data sources have led to inconsistent findings in the association between use of CNS drug use in pregnancy and CNS outcomes. Researchers should allow for study designs with clearly defined exposure periods, at the very least in trimesters, and use advanced confounding adjustment methodology to increase the accuracy of the findings.

Number of words in manuscript: 5739

Number of figures: 3

Number of tables: 1

Number of electronic supplementary materials: 4

Key points:

- Pregnancies as identified in administrative databases/registries with large sample sizes are highly likely to be representative of the general population.

- Explicit linkage records, between mothers and their children, should be used to study infant outcomes and drug exposure in pregnancy.

- Advanced methods such as sibling-matched models and propensity score methods can minimise potential bias and improve the accuracy of findings.

- A pre-specified time of drug exposure and an adequate follow-up period are essential in pregnancy safety studies.

- Adequate and validated outcome instruments/scales (also chosen based upon infant age) should be used.

1. Introduction

There has been an ongoing debate about whether pregnant women should take central nervous system (CNS) medications such as antidepressants (ADs), antipsychotics (APs) and/or antiepileptic drugs (AEDs) given the potential adverse outcome for the foetus. This must be weighed up against the risk of untreated depression, schizophrenia or epilepsy. Studies into the teratogenicity of the older generations of AEDs have shown that intrauterine exposure to anticonvulsants like valproate acid and phenytoin are associated with congenital malformations such as congenital heart anomalies, neural tube defects, cleft lip/plate and developmental delays (1-5). Findings on the potential adverse outcomes of ADs like selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs) or tricyclic antidepressants (TCAs), however, remain conflicting with some studies showing a statistically significant increase in the risk of congenital heart defects, neurodevelopmental disorders including autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and neonatal convulsions (6-8). Pharmacologically, all CNS drugs can cross not only the blood-brain barrier for their intended action in the pregnant woman, but also the placenta, which could have unintended effects on the development of the foetus (9-11). Previous studies have shown that antipsychotic use in pregnancy (in particular some second generation APs such as olanzapine and clozapine) may lead to the development of gestational diabetes (12), and thus an increased risk of CNS-related birth defects. However, there is a lack of concrete evidence for a causal association between gestational APs use and adverse CNS outcome in offspring (13-16). The possible link between in-utero exposure to CNS medication and adverse CNS effects in children creates a dilemma in the pharmacological management of women with severe neurological or psychiatric disorders both when they are trying to conceive, and during pregnancy. The safety of CNS drugs use in pregnancy has become an important clinical issue and has been extensively studied over the past few decades.

Randomised controlled trials (RCTs) are usually regarded as the gold standard for evaluating medication efficacy and safety in the general population. However, it is not feasible to conduct RCTs in pregnant women due to ethical concerns (14, 17). Observational studies, including case-control and cohort studies, have some advantages over RCTs. One such advantage is the representativeness of the general population due to the large sample size available for analysis (18). Moreover, long-term effects and rare outcomes on the CNS of the offspring can be evaluated in observational studies. Any potential risk of neurodevelopmental disorders such as ASD and ADHD require a longer period of observation for reliable detection, since the diagnosis of these conditions is generally not made until some

considerable time after the neonatal period. Observational studies of medication safety in pregnancy are therefore essential to complement information from RCTs (17, 19).

Systematic reviews and meta-analyses of observational studies are often undertaken to evaluate the clinical effects of medication in pregnant women. However, these analyses often focus on the extent of the clinical adverse effects and may not give sufficient attention to the variations in methodologies used in the studies. Therefore, this methodological review was conducted to assess the methodological characteristics of existing case-control and cohort studies, which investigate the association between CNS drugs use in pregnancy and adverse CNS outcomes in neonates and children.

2. Methods

2.1 Systematic literature search

A systematic literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist using PubMed to search for observational studies that investigated the association between the use of CNS drugs during pregnancy and adverse CNS outcomes in neonates and children between 1 January 1946 and 21 September 2017. The following combination of search terms was used: (Pregnancy) AND (CNS outcomes) AND [(Antidepressants) OR (Antipsychotics) OR (Antiepileptics)]. These search terms were chosen based on recommendations by Medical Subject Headings (MeSH) terms in PubMed as well as the Cochrane Pregnancy and Childbirth Group Search Strategy (20). The complete list of search terms can be found in Electronic Supplementary Material 1.

2.2 Inclusion and exclusion criteria

Observational studies that used either case-control or cohort design and which reported the association between gestational AEDs/ADs/APs use and infant CNS outcomes (neurodevelopmental disorders, convulsions and congenital anomalies of CNS) were included. Articles written in languages other than English were excluded. Animal studies, case reports, case series, cross-sectional studies, reviews, systematic reviews and meta-analyses were excluded.

2.3 Screening and data extraction

All articles were screened independently by two authors (PH and MC) in order to identify relevant studies based on titles and abstracts. Full texts of potentially relevant papers were also reviewed in case the titles and abstracts were not adequate for determining the relevance of the study. Data extraction was conducted independently for all the included studies using a standardised data collection form. Any discrepancies between the two reviewers were resolved through discussion. Data extraction included the year of publication, data source, method for establishing linkage between mother and child, study duration, study site, study design, sample size, types of drug used, types of CNS outcomes,

inclusion criteria, exclusion criteria, identification of study groups, time period of exposure measurement, statistical method, and confounding adjustment method. Three types of data source were identified: administrative databases/registries, ad hoc disease registries and ad hoc clinical samples. Briefly, in this study we defined administrative databases/registries as electronic medical or insurance record systems, often used to facilitate the operation of hospitals, general practices or community pharmacies. An ad hoc disease registry, on the other hand, was defined as a registration system set up for the systematic collection of data for a specific disease state or exposure group, usually for the purpose of epidemiological analysis or for carrying out follow-up studies and research. For studies not using any database and/or registry as data sources, the data source was considered to be an ad hoc clinical sample, with patients recruited in hospitals/clinics or through information services.

2.4 Review and analyses

This methodological review focused on the data collection and study designs of the included observational studies. In particular: the characteristics of the included studies with reference to the different types of data sources used, methodologies used to address underlying biases and confounders, and statistical analysis methods applied. A descriptive summary detailing study design, types of drug exposure and types of CNS outcomes is presented in Electronic Supplementary Material 3.

Fig 1 PRISMA flow chart for studies inclusion

3. Results

A total of 3,802 studies were retrieved from the PubMed database from 1 January 1946 to 21 September 2017 (Fig 1). One hundred and eleven were deemed to be relevant and included. The full list is found in Electronic Supplementary Material 2. Of the 111 studies, twenty-five (23%) were case-control studies (21-45) and eighty-six (77%) were cohort studies (1, 6, 7, 46-128), although five of the cohort studies did not include an unexposed group as control for comparison (73-76, 92). Sixty-one (55%) were carried out in European countries (21, 23, 24, 28, 29, 32-34, 36, 38, 39, 42, 43, 46, 48, 49, 52, 54-56, 59, 60, 62, 64, 68-72, 77, 79-81, 83, 85, 87-89, 91-94, 97, 99, 101, 103, 105-107, 110, 116-123, 125, 126, 128), twenty (18%) in the United States (1, 6, 22, 25, 26, 30, 31, 40, 41, 45, 47, 57, 61, 65, 67, 75, 76, 78, 86, 100), nine (8%) in Canada (7, 51, 53, 63, 82, 96, 100, 102, 124), seven (6%) in Australia (44, 111-115, 127), and the remaining studies were in Japan, India, Hong Kong, Israel and Egypt (23, 35, 37, 50, 58, 66, 73, 74, 84, 90, 95, 98, 104, 108, 109). In addition, the types of CNS

outcomes being investigated included neurodevelopmental disorders, convulsions and congenital anomalies of CNS such as neural tube defects, spina bifida, anencephaly and microcephaly. While thirty (27%) studies specifically focused solely on one CNS outcome, others investigated all congenital malformations and included CNS as one of the outcome subgroups for analysis.


Fig 2 Trend in absolute number of relevant studies included from 1978 to 2017

3.1 General characteristics of included articles

As shown in Fig 2, the absolute number of relevant studies peaked in 2013. The number of relevant studies has increased gradually over time and the proportion of included articles over the total number of papers, found using the search terms, has remained around 2-8% in the last two decades. The first study that was included in this review, investigating gestational antiepileptic drug use, was published in 1978. Publications focused on AED use made up the majority of the included studies until 1993, when the first observational study focussed on antidepressant (fluoxetine) use in pregnancy was published (100). There has been a gradual rise in antidepressant research from 2004 onwards and these have exceeded the number of AEDs studies since 2007. In 2017, antidepressant studies contributed to the vast majority of the included studies. Only one study on antipsychotics was identified in this review (128).

3.2 Types of data sources used

Of the 111 studies, forty-six (41%) obtained their data from an administrative database/registry (6, 7, 23-30, 32-34, 40, 42, 45-49, 51, 53, 55-57, 61, 62, 69, 71, 72, 77, 82, 83, 85, 88-90, 101, 105, 106, 118, 121, 122, 124, 126, 128), twenty (18%) from an ad hoc disease registry (36, 38, 39, 41, 44, 54, 65, 68, 93, 94, 98, 100, 108, 109, 111-115, 127), forty-one (37%) from an ad hoc clinical sample (1, 21, 22, 31, 35, 37, 43, 50, 52, 58-60, 63, 64, 67, 70, 73-76, 78, 84, 86, 87, 91, 92, 95-97, 99, 102-104, 107, 110,

116, 117, 119, 120, 123, 125), and four (4%) studies did not clearly specify the data source (66, 79-81). Selection of data sources has changed over time with administrative databases/registries comprising large numbers of participants becoming the most commonly used data source in recent years.

Exposure groups were identified by using code lists or by using information from interviews or self-reports recorded during the antenatal care service in administrative databases/registries. Exposure identification methods in ad hoc disease registries and the ad hoc clinical samples usually consisted of retrospective reviews of medical records, questionnaires, or examinations. For more details, see Electronic Supplementary Material 3.

3.3 Linkage between mother and child

Few studies explicitly reported the linkage methods between mother and child, but linkage methods were ascertainable in eighty-five (77%) of the included studies (1, 7, 21, 25, 26, 28, 31-36, 38-46, 48-50, 52-60, 63-66, 68-73, 77, 78, 83, 85-90, 95-108, 110-128). In general, there are two types of mother-child linkage methods, namely deterministic linkage and probabilistic linkage. Deterministic linkage is based on a full agreement of a unique identifier or a set of common identifiers (129). Studies using administrative databases/registries mostly included mother-child pairs identified through deterministic linkages. One example of an effective deterministic linkage method is the Clinical Data Analysis and Reporting System (CDARS) in Hong Kong, which matches the identification numbers of mother and child, together with the delivery date and hospital. Accuracy is further ensured by linking the records permanently and immediately after delivery (90). Twenty-eight of the eighty-five studies (7, 25, 26, 28, 42, 49, 50, 52, 54-59, 63, 65, 70, 73, 85, 88-90, 101, 105, 108, 118, 121, 122) were conducted using deterministic linkage (129). Probabilistic linkage is an approach using a set of variables to define the unique identity of an individual, such as maternal date of birth, maternal name and residence code (130) and linking up pregnant women with children that have a high probability to be a mother-child pair. Fifty-seven studies used probabilistic linkage. An example of a study using probabilistic linkage is the study using UK Clinical Practice Research Datalink (CPRD) which investigated the risks and benefits of psychotropic drugs use in pregnancy (128). Pregnant women and their children were linked based on the same general practice registration as well as the same family/household identifier. The maternal delivery date and child's month of birth were also required to be within 6 months.

3.4 Types of study designs adopted to deal with confounding factors

Sixty-six (59%) included studies compared women taking ADs/AEDs/APs with a control group defined as pregnant women without the corresponding exposure (21-24, 28, 32-41, 43, 45, 46, 49, 54, 56-58, 60, 62-64, 66, 68, 71-77, 79, 84, 86, 88, 91-94, 96-99, 102-105, 107, 109, 110, 113, 114, 116, 117, 119, 120, 124-128). However, there was no information regarding whether the pregnant women were untreated mothers with depression/epilepsy/schizophrenia or healthy mothers without depression/epilepsy/schizophrenia. Sibling-matched models were used to control for the shared genetic,

maternal health status, familial and social factors in four (4%) studies (83, 90, 101, 106). In addition, three (3%) studies (42, 90, 106) conducted negative control analysis (131). Negative control analysis is usually applied to explore common forms of selection and measurement bias in observational studies (132).. Two of the studies conducted using negative control analysis used paternal drug exposure (Sujan et al. (2017) and Rai et al. (2013)). A recently published cohort study by Man et al. (2017) compared two negative control comparisons: pre-conception ADs users and never users; and never users with and without psychiatric disorders. To evaluate whether the exposure effect was due to the drug rather than the maternal disease state (depression/epilepsy/schizophrenia), control groups with alternative treatment were used in in thirty-three (30%) studies (1, 31, 42, 44, 47, 48, 50, 52, 55, 65, 67, 69, 70, 78, 80-82, 85, 87, 89, 90, 95, 100, 101, 108, 111, 112, 115, 118, 121-123, 128). The propensity score method was applied to minimise the effect of confounding in one (1%) study (101).

3.5 Statistical Analysis

Of the 111 included studies, forty-two (38%) conducted univariate analysis in which only the mean, standard deviation, absolute risk, percentage and incidence of adverse outcomes were reported, or the results were merely tabulated in absolute counts (21, 38, 43, 46, 47, 50, 60, 63, 64, 66-68, 73-76, 79-82, 84, 86, 87, 92, 94, 95, 97-100, 102-104, 107, 109, 110, 115-117, 119, 120, 124). The remaining sixty-nine (62%) studies used multivariable regression analysis, such as multiple linear regression, Poisson regression, logistic regression or Cox proportional hazard regression to provide adjusted risk estimates in the form of odds ratios (OR) and hazard ratios (HR) (1, 6, 7, 22-37, 39-42, 44, 45, 48, 49, 51-59, 61, 62, 65, 69-72, 77, 78, 83, 85, 88-91, 93, 96, 101, 105, 106, 108, 111-114, 118, 121-123, 125-128).

The proportion of univariate and multivariable analysis for each data source subgroup is shown in Fig 3. In total, the proportion of studies using multivariable analysis and univariate analysis is 62% and 38%, respectively. Multivariable analysis was mostly used in studies utilising administrative databases/registries (38/46, 83%), and least in studies using ad hoc clinical samples as their data source (15/41, 37%). The reverse trend was seen for univariate analysis.

More complex methods have been used in recent studies. Studies using univariate analysis were commonly found in the early years.

Proportion of univariate and multivariable analysis in each data source subgroup

Fig 3 The proportion of univariate and multivariable analysis in each data source subgroup

4. Discussion

This is the first methodological review of observational studies of CNS drugs use in pregnant women and the CNS outcomes of their children. The findings show that most of the research to date has investigated the association between gestational CNS drugs use and infant CNS outcome using cohort studies. There has been an increase in these studies over the last 20 years and the vast majority of these have been reported in western countries. There has been more research on ADs than AEDs during the last five years.

Due to the unfavourable prognosis of epilepsy in pregnant women, such as a higher risk of death, preeclampsia, preterm labour, and stillbirth, much effort was invested in developing a registry for epilepsy patients. Registries such as the European Registry of Antiepileptic Drugs and Pregnancy (EURAP), the UK Epilepsy and Pregnancy Registry, and the North American AED Pregnancy Registry contain detailed information about participants and have become a valuable data source for research (65, 133-135). The well-established teratogenicity of AEDs may be associated with the gradual decrease in related observational studies as clinicians avoid prescribing teratogenic medications.

Only one study was found investigating the relationship between the use of antipsychotics in pregnancy and CNS outcomes in children. The prescription of APs in pregnancy has increased over the last ten years, but the proportion of gestational APs use is still less than 1% (136, 137). Further research in this area is warranted.

4.1 Types of data source adopted

4.1.1 Administrative database/registry

A large sample size is one of the main advantages of using administrative databases/registries for observational studies. As well as being highly representative of the general population, using these registries can also increase the statistical power of the study, thus reducing standard error and improving accuracy in the detection of any effect. The pre-existing and on-going accrual of patient information in an administrative database/registry, with its primary purpose being to record health information saves time, money and the manpower involved in the data collection process compared to studies with ad hoc clinical samples as the data source.

Nonetheless, administrative databases/registries are not without some limitations. For the identification of exposures and cases, most use international coding systems such as the Anatomical Therapeutic Chemical Classification System (ATC) for medications or the International Statistical Classification of Diseases and Related Health Problems (ICD) for diagnoses. In case of misclassification or changes in coding of disease over time, significant discrepancies in diagnosis may affect the validity of the study results. For instance, the diagnostic criteria of psychiatric disorders, the Diagnostic and Statistical Manual of Mental Disorders (DSM), has been evolving constantly from DSM-III in 1980 to DSM-V in 2013. Moreover, many included studies use standard coding such as ICD codes, both 9th and 10th versions, but the accuracy of the coding varies between conditions, databases and registries (138-142). Only Rai et al., Viktorin et al. and Sujan et al., which used data from Swedish databases, performed the relevant validation for the purposes of their study (101, 106, 122, 143-145).

Biases in the collection, analysis, or interpretation of the data may result in invalid study conclusions (146). Three main types of bias are selection bias, information bias (also known as misclassification) and confounding bias (147). Limiting selection criteria to live births is common in administrative claims data and will lead to selection bias. Misclassification of the outcome disease(s), would bias the estimate towards null and consequently, underestimate the corresponding effect of the medications. Another type of misclassification, exposure misclassification, probably occurs in all observational studies as we often have data on prescriptions or dispensing, but not actual use (148). The misclassification of exposure or disease status can be considered as either differential or non-differential. Non-differential misclassification will bias the estimate towards the null (149). Conversely, differential misclassification occurs when the proportions of subjects misclassified differ between the study groups. That is, the probability of exposure being misclassified is dependent on outcome, and vice versa. The results could therefore be either overestimated or under-estimated (147, 150). An accurate exposure assessment is vital to minimise the bias. Although measurements of drug concentration in maternal blood are not available in most of the data sources, this could potentially an ideal approach to validate exposure status. In terms of confounding bias, data from an administrative database/registry may not comprehensively cover all potential confounders, particularly lifestyle and behavioural characteristics, including diet, exercise, alcohol and tobacco use etc. (138).

Record linkages between registries are generally classified into deterministic linkage and probabilistic linkage methods (151). Deterministic linkage methods require exact agreement of the pre-determined matching variables to result in a linkage. Probabilistic linkage methods use information on some matching variables, and allow disagreement between matching variables if the degree of matching is determined to be greater than an accepted cut-off weight. Our findings showed that most studies using an administrative database/registry perform linkage through unique personal identification numbers, the deterministic linkage method. The major limitation of deterministic linkage methods is that the method is prone to entry errors and missing values, which would reduce the number of true matches, and hence the sensitivity and positive predictive value of the linkage (152). The type of identifiers used also has an effect on linkage quality. Direct identifiers, such as unique identifiable numbers (e.g. Social Security Number), are generally regarded as the gold standard (153). However, indirect identifiers (e.g. name, sex, date of birth, address, date of admission etc.) are commonly used in different studies due to regulatory and availability issues. It was shown in a validation study that record linkage using name code in place of full name record has low sensitivity but high specificity, resulting in under-estimated risks (154). This illustrates that the quality of the linkage method can significantly affect the outcome of a database-based observational study, and reporting of linkage methods is necessary, especially in database and registry settings. Lastly, medical records used in private clinics or specialist care can often not be identified in or linked with records in administrative databases/registries and this may contribute to the problem of underestimation of risk. Future studies could consider the use of probabilistic linkage to improve the quality of linkages if deterministic linkage is not possible.

4.1.2 Ad hoc disease registry

Ad hoc disease registries recruit patients with a specific exposure, for example, pregnant women with exposure to AEDs or epilepsy. They are usually set up for postmarketing surveillance and monitoring of any potential adverse effects of medication or treatment, as well as providing data for research purposes.

One strength of ad hoc disease registries is that they often have more complete data compared to administrative databases/registries, as the information on subject characteristics, treatment details and outcomes are better documented and reviewed by investigators. They also have long-term follow up, and comply with registry-specific standards and measurements, as required by the Registers of Patient Registries (RoPR), to ensure data validity (138). Data quality is further enriched by having additional information that cannot be collected from administrative databases/registries, e.g. socioeconomic status and lifestyle characteristics of the study subjects.

However, the coverage of an ad hoc disease registry is lower as it contains a much smaller sample size and requires the voluntary enrolment of subjects, e.g. the UK Epilepsy and Pregnancy Register (68), thus reducing the representativeness and generalisability of study results. Selection bias

could also be introduced as the people who are willing to enrol on the registry may be more health conscious or healthy, thus potentially underestimating the actual drug effect.

A major limitation of an ad hoc disease registry is the lack of an untreated control group. An ad hoc disease registry in general enrols subjects with the specific disease, and most likely, with the specific drug exposure (ADs/AEDs/APs) which could lead to a shortfall in calculating the incidence of the outcome of interest. However, studies using data from these ad hoc disease regstries usually have active control groups i.e. monotherapy vs polypharmacy, which has the advantage of minimising confounding by indication. For instance, a study using the North American AED Pregnancy Registry (65) compared specific AED monotherapy such as valproate, phenobarbital and topiramate with lamotrigine treatment. It is worth noting that although such comparisons help to differentiate different drugs, they can only be used when teratogenicity is already well-established in the drug class.

4.1.3 Ad hoc clinical sample

Since an ad hoc clinical sample involves the direct recruitment of patients from hospitals, clinics or information services, sample sizes are usually small and more manpower, money and time is required for the primary data collection process. Results of single centre ad hoc clinical sample studies are not very generalisable. They also have an increased risk of participants being lost-to-follow up due to their prospective nature. However, ad hoc clinical samples may have comprehensive data as any information which is not available in the database can be obtained from a questionnaire.

Summaries of the advantages and disadvantages of different data sources are shown in Table 1. An administrative database/registry might be the primary choice as it is more likely to be representative of the general population when dealing with potential bias.

Table 1 Advantages and disadvantages of different data sources

DATA SOURCE	ADVANTAGES	DISADVANTAGES
Administrative database/registry	- Large sample size - More representative of the general population - Higher statistical power and accuracy - Reduction in standard error - Time, cost and manpower saving	- May have significant discrepancies in diagnosis due to misclassifications or under-recording and/or change in coding of disease over time - Information captured may not be adequate to address all confounding factors - Accurate linkage method between mothers and children may not be available - Limited to the scope of the data coverage and may not have sufficient information from other healthcare providers - Selection bias (i.e limiting selection criteria to live births), information bias (i.e. misclassification of the

		outcome and exposure) and confounding bias (i.e. underlying confounders such as lifestyle and behavioural characteristics)
Ad hoc disease registry	- More comprehensive subjects' information - Additional information can be collected via surveys or interviews if necessary - Allows for long-term follow up if necessary - Active control group involved	- Smaller sample size compared to administrative databases - Lower coverage and representativeness of the general population - Lack of untreated control group
Ad hoc clinical sample	- More comprehensive data than registry data - Additional information can be collected if necessary	- Smaller sample size compared to both administrative databases and ad hoc disease registries - More manpower, cost and time required compared to both administrative databases and ad hoc disease registries - Lack of generalisability and representativeness - Higher risk of loss-to-follow-up

4.2 Confounding factors management and study design

While many studies have observed that congenital malformations or neurodevelopmental disorders in infants are associated with maternal use of ADs and AEDs during pregnancy, confounders can impact the validity of estimates obtained from data and are a major source of bias (17, 90). Failing to explore the true effects of medication exposure can result in inappropriate therapies and adverse outcomes; thus, it is necessary to detect and control for confounding using suitable methods to obtain unbiased effect estimates (17, 155).

The general covariates in pregnancy observational studies are maternal age, parity, maternal smoking and alcohol use. Multivariable adjustments in regression models were commonly applied to deal with these covariates in our included studies. The use of advanced methods such as propensity score (PS) methods, which is particularly beneficial for common treatments and rare outcome observations, was still limited. Applications including matching, stratification, adjustment, and weighting (17) can be used to balance patients' characteristics in groups. PS can detect possible residual confounding and therefore decrease the potential bias (156). Logistic regression is the typical approach for estimating the PS with the exposure of interest as the dependent variable and confounders as independent variables. Although the application of PS has increased in safety studies, it is still used far less than multivariable regression (17, 157).

Confounding by indication seems to be one of the most significant residual confounding effect in the context of our review (158). Any CNS outcome in children might be a real effect of maternal CNS drug use during pregnancy, but might also be a confounding effect due to the disease state of the pregnant mother who needs to take the medication. A straightforward analysis between users and non-

users of CNS drugs fails to control for confounding by indication as the adverse effect might be due to the underlying disease of the mother, and not because of the maternal use of any medication. In our review, most included studies used control groups (matching and restriction) to deal with confounding. For example, a study using Hong Kong population based electronic medical records selected a control group using antipsychotics as an active comparator in order to adjust for confounding by indication (90). Furthermore, for some diagnoses such as depression, a scale measuring symptom severity is even better than just a dichotomous variable (e.g. depression: yes/no). For drugs used for several indications (e.g. lamotrigine and bipolar disorder/epilepsy), risks could be compared across indications as well.

We identified sibling-matched analyses and negative control analyses to adjust crude estimates for confounding factors such as socioeconomic demographics and genetic factors in our included studies. Use of sibling-matched analyses is most suitable for ascertaining the relationship between prenatal exposures to CNS substances and foetal outcomes when confounders are shared between siblings, and there are no carryover effects between siblings (159, 160). One main advantage is that, by separating the potential genetic and familial components of the disease status from exposure to medications (17), the results are less likely to be biased due to confounding. Sibling designs may be unbiased but only if all confounders are perfectly shared by within-pair members, and there is no random measurement error of the exposure (160). However, the current approach normally assumes a stable familial context, i.e. the composition of family is assumed to be static and unchanging. This might not be the case as the family might not be the same over time. The socioeconomic status of the family might change, and the birth order or the inter-pregnancy interval between different foetuses might affect various outcome such as autism (161). Since many real sibling comparisons may suffer from one or both of above biases, the application of sibling-matched analyses should be given due consideration (160).

Negative control analysis could eliminate the possibility that the adverse outcome is due to the effect of alternative variables instead of the exposure factor being studied. Measuring drug exposure before conception is common negative control method. If a significant difference in the risk of adverse CNS outcomes is found and associated with preconception drug exposure, this indicates that potentional maternal psychiatric disorders have an effect on adverse outcomes as the negative control group was not exposed to the drug of interest during pregnancy. Also, negative controls enable identification of the existence and direction of bias, both in terms of recall bias and selection bias due to uncontrolled confounding (131). Paternal exposure to CNS substances during pregnacy period as the negative control exposure is biologically implausible as paternal exposure would not affect the fetal outcome. However, paternal exposure may, in theory, affect maternal exposure via behavioural, environmental and social influences (162). In this case, if paternal exposure during pregnancy to some extent determines maternal exposure, the outcomes would be considered to be due to the confounding of unmeasured factors within the families rather than the exposure of interest.

Marginal structural models (MSMs) and instrumental variable methods are advanced methods for confounding control in pregnancy medication safety studies (17). MSM use time-varying exposures and measure confounders which are highly related in pregnancy studies due to the variation in foetal vulnerability and the tendency of women to alter their gestational medication use (17, 163, 164). However, MSMs cannot provide unbiased effect estimates when confounders are unmeasured. On the other hand, instrumental variable analyses can address both measured and unmeasured confounding factors, and so instruments which meet all the strict assumptions may imitate the results from a randomised trial (17), whereas untestable assumptions could result in bias amplification. As no included study has adopted these two methods, it is worth noting that there are alternatives for researchers to consider as primary or secondary analyses in further research.

We identified some issues in the included studies such as inadequate follow-up, unspecified time to exposure, or even use inappropriate confounding approaches, which could lead to overestimation or underestimation of potential risks. An example is the inconsistent findings by several observational studies investigating the association between ADs and ADHD (25, 26, 61, 83, 106). While ADHD is often clinically diagnosed after the age of five (90), few studies (61, 90) have restricted the samples to children at least five years old. Therefore, the resulting estimates may not truly reflect the actual risk. Methods such as the use of adequate follow-up and specified exposure time are therefore necessary to avoid underlying bias, imprecision and confusing interpretation of estimates. When focusing on congenital malformations, investigators should attempt to study the time period of exposures relevant to the pathogenesis of the condition where appropriate. For instance, the critical period for neural tube development is 17-30 days of gestation (165). Thus, for any of the neural tube defects, e.g. anencephaly and spina bifida, they are more likely to be influenced by exposure factors in the first trimester and cannot be caused by exposure later in pregnancy. However, many included studies did not specify the time period of the drug exposure, or merely set it as 'during pregnancy', which could potentially affect the accuracy of results. Moreover, the definition of pregnancy period should be considered carefully that when counting gestational days, it could preferably be clarified that 'days of gestation' are claculated from the first day of the last menstrual bleeding day rather than the fertilisation day which is two weeks later.

4.3 Limitations and challenges

A limitation of this methological review is that we only seached articles in PubMed and we may not have included all potential studies on maternal CNS drug use and infant CNS outcomes. For the purposes of this review, we selected a wide varity of observational studies focusing on pregnancy exposure with different methodological characteristics.

It is hard to define whether the quality assessment such as Newcastle-Ottawa Scale (NOS) can provide the true study quality although we often consider a higher NOS score represent a higher study

quality. Researchers are supposed to be critical when conducting a meta-analysis that the more 'inferior' studies included in the meta-analysis, the more misleading the conclusion could be. To exclude the 'inferior' studies from the meta-analysis might be a better choice which can provide reliable risk calculations.

4.4 Clinical implication and recommendation

Although there are some drawbacks of observational studies, they are currently the only way of assessing medication safety during pregnancy. There is no perfect study design for all studies. However, several suggestions for further studies could be considered. Firstly, using an appropriate time period of exposure (by trimester or even week of pregnancy) and adequate follow-up are vital for accurate results. Failure to evaluate the right observation period could mask a potential effect, i.e. bias towards null. Secondly, an administrative database/registry is a good first choice for a representative study sample, providing accurate and reliable record linkage between mothers and their children is possible. Inaccurate linkage between mother-child pairs could results in misclassification of both exposures and outcomes and would underestimate the study findings. Third, regardless of the types of data source selected, it is important to address confounding, preferably with more than one of the above mentioned advanced methods in order to avoid potential biases. In particular, confounding by indication is the most important factor to consider in observational studies on CNS drugs use in pregnancy and CNS outcomes in offspring. Unmeasured or unaddressed confounding could lead to biased results and subsequently to incorrect conclusions. Last but not least, in order to account for multiple confounding factors, multivariable analyses such as logistic regression analysis are recommended to provide more precise risk estimates. A flow chart of the study design process can be seen in Electronic Supplementary Material 4.

5. Conclusion

While publications of observational studies investigating the association between gestational CNS drug use and adverse CNS outcome in neonates have increased over the years, the findings have been inconsistent and sometimes contradictory. This could be due to multiple factors, such as the underlying limitations of different study designs and estimations used. The discrete choices of control groups and data sources, whether potential confounders are addressed appropriately, the sample size involved, or even study period, duration, inclusion and exclusion criteria may all also contribute to differences in the final results and conclusions. Investigators should be mindful of these issues and focus on optimising study designs as well as adopting the most suitable statistical analysis method for their hypothesis in order to minimise potential bias and confounders. Addresing these factors will achieve better precision, validity and generalisability of results.

Compliance with Ethical Standards:

References

1.   Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. The New England journal of medicine. 2001;344(15):1132-8.
2.   Bruno MK, Harden CL. Epilepsy in Pregnant Women. Current treatment options in neurology. 2002;4(1):31-40.
3.   Adab N. Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful? CNS drugs. 2006;20(10):791-800.
4.   Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs. 2007;67(18):2727-46.
5.   Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurologic clinics. 2009;27(4):993-1002.

6.	Hayes RM, Wu P, Shelton RC, Cooper WO, Dupont WD, Mitchel E, et al. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. American journal of obstetrics and gynecology. 2012;207(1):49.e1-9.

7.	Boukhris T, Sheehy O, Mottron L, Berard A. Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children. JAMA pediatrics. 2016;170(2):117-24.

8.	Man KK, Tong HH, Wong LY, Chan EW, Simonoff E, Wong IC. Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: a systematic review and meta-analysis of observational studies. Neuroscience & Biobehavioral Reviews. 2015;49:82-9.

9.	Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, et al. Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis. Neuroscience and biobehavioral reviews. 2018;86:1-11.

10.	Kendall-Tackett K, Hale TW. The use of antidepressants in pregnant and breastfeeding women: a review of recent studies. Journal of Human Lactation. 2010;26(2):187-95.

11.	Rampono J, Simmer K, Ilett K, Hackett L, Doherty D, Elliot R, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42(03):95-100.

12.	Bodén R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Archives of general psychiatry. 2012;69(7):715-21.

13.	Anderson JL, Waller DK, Canfield MA, Shaw GM, Watkins ML, Werler MM. Maternal obesity, gestational diabetes, and central nervous system birth defects. Epidemiology. 2005;16(1):87-92.

14.	Kulkarni J, Storch A, Baraniuk A, Gilbert H, Gavrilidis E, Worsley R. Antipsychotic use in pregnancy. Expert opinion on pharmacotherapy. 2015;16(9):1335-45.

15.	Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. Journal of Psychiatric Practice®. 2009;15(3):183-92.

16.	Raha S, Taylor VH, Holloway AC. Effect of atypical antipsychotics on fetal growth: is the placenta involved? Journal of pregnancy. 2012;2012.

17.	Wood ME, Lapane KL, van Gelder M, Rai D, Nordeng HME. Making fair comparisons in pregnancy medication safety studies: An overview of advanced methods for confounding control. Pharmacoepidemiology and drug safety. 2018;27(2):140-7.

18.	Lao KS, Chui CS, Man KK, Lau WC, Chan EW, Wong IC. Medication safety research by observational study design. International journal of clinical pharmacy. 2016;38(3):676-84.

19.	Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages. Nature Reviews Rheumatology. 2007;3(12):725.

20.	Alfirevic Z KE, Dowswell T, et al. . Which method is best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis.: Southampton (UK): NIHR Journals Library; 2016 Aug. Available from: https://www.ncbi.nlm.nih.gov/books/NBK379828/.

21.	Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, et al. The longer term outcome of children born to mothers with epilepsy. Journal of neurology, neurosurgery, and psychiatry. 2004;75(11):1575-83.

22.	Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. The New England journal of medicine. 2007;356(26):2684-92.

23.	Arpino C, Brescianini S, Robert E, Castilla EE, Cocchi G, Cornel MC, et al. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia. 2000;41(11):1436-43.

24.	Bertollini R, Mastroiacovo P, Segni G. Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC). European journal of epidemiology. 1985;1(1):67-72.

25.	Castro VM, Kong SW, Clements CC, Brady R, Kaimal AJ, Doyle AE, et al. Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study. Translational psychiatry. 2016;6:e708.

26.	Clements CC, Castro VM, Blumenthal SR, Rosenfield HR, Murphy SN, Fava M, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry. 2015;20(6):727-34.

27.	Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Archives of general psychiatry. 2011;68(11):1104-12.

28.	de Jonge L, Zetstra-van der Woude PA, Bos HJ, de Jong-van den Berg LT, Bakker MK. Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection. Drug safety. 2013;36(11):1069-78.

29.	Gidaya NB, Lee BK, Burstyn I, Yudell M, Mortensen EL, Newschaffer CJ. In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. Journal of autism and developmental disorders. 2014;44(10):2558-67.

30.	Gurney JG, Mueller BA, Preston-Martin S, McDaniel AM, Holly EA, Pogoda JM, et al. A study of pediatric brain tumors and their association with epilepsy and anticonvulsant use. Neuroepidemiology. 1997;16(5):248-55.

31.	Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics. 2014;133(5):e1241-8.

32.	Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ (Clinical research ed). 2010;341:c6581.

33.	Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. The New England journal of medicine. 2010;362(23):2185-93.

34.	Kallen AJ. Maternal carbamazepine and infant spina bifida. Reproductive toxicology (Elmsford, NY). 1994;8(3):203-5.

35.	Kondo A, Morota N, Ihara S, Saisu T, Inoue K, Shimokawa S, et al. Risk factors for the occurrence of spina bifida (a case-control study) and the prevalence rate of spina bifida in Japan. Birth defects research Part A, Clinical and molecular teratology. 2013;97(9):610-5.

36.	Luteijn JM, Morris JK, Garne E, Given J, de Jong-van den Berg L, Addor MC, et al. EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication. British journal of clinical pharmacology. 2016;82(4):1110-22.

37.	Maged A, Elsherbini M, Ramadan W, Elkomy R, Helal O, Hatem D, et al. Periconceptional risk factors of spina bifida among Egyptian population: a case-control study. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2016;29(14):2264-7.

38.	Medveczky E, Puho E, Czeizel EA. The use of drugs in mothers of offspring with neural-tube defects. Pharmacoepidemiology and drug safety. 2004;13(7):443-55.

39.	Meijer WM, de Walle HE, Kerstjens-Frederikse WS, de Jong-van den Berg LT. Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. Reproductive toxicology (Elmsford, NY). 2005;20(2):203-7.

40.	Polen KN, Rasmussen SA, Riehle-Colarusso T, Reefhuis J. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. Birth defects research Part A, Clinical and molecular teratology. 2013;97(1):28-35.

41.	Queisser-Luft A, Eggers I, Stolz G, Kieninger-Baum D, Schlaefer K. Serial examination of 20,248 newborn fetuses and infants: correlations between drug exposure and major malformations. American journal of medical genetics. 1996;63(1):268-76.

42.	Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. Bmj. 2013;346:f2059.

43.   Sabers A, aRogvi-Hansen B, Dam M, Fischer-Rasmussen W, Gram L, Hansen M, et al. Pregnancy and epilepsy: a retrospective study of 151 pregnancies. Acta neurologica Scandinavica. 1998;97(3):164-70.

44.   Vajda FJ, Hitchcock A, Graham J, Solinas C, O'Brien TJ, Lander CM, et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. European journal of neurology. 2006;13(6):645-54.

45.   Werler MM, Ahrens KA, Bosco JL, Mitchell AA, Anderka MT, Gilboa SM, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Annals of epidemiology. 2011;21(11):842-50.

46.   Almgren M, Kallen B, Lavebratt C. Population-based study of antiepileptic drug exposure in utero--influence on head circumference in newborns. Seizure. 2009;18(10):672-5.

47.   Annegers JF, Hauser WA, Elveback LR, Anderson VE, Kurland LI. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. International journal of epidemiology. 1978;7(3):241-7.

48.   Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology. 2005;64(11):1874-8.

49.   Artama M, Ritvanen A, Gissler M, Isojarvi J, Auvinen A. Congenital structural anomalies in offspring of women with epilepsy--a population-based cohort study in Finland. International journal of epidemiology. 2006;35(2):280-7.

50.   Barqawi R. Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2005;11(4):601-5.

51.   Boukhris T, Sheehy O, Berard A. Antidepressant Use in Pregnancy and the Risk of Attention Deficit with or without Hyperactivity Disorder in Children. Paediatric and perinatal epidemiology. 2017;31(4):363-73.

52.   Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, Garcia-Finana M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of neurology, neurosurgery, and psychiatry. 2013;84(6):637-43.

53.   Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. Jama. 2017;317(15):1544-52.

54.   Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of neurology, neurosurgery, and psychiatry. 2014;85(9):1029-34.

55.   Cantarutti A, Merlino L, Giaquinto C, Corrao G. Use of antidepressant medication in pregnancy and adverse neonatal outcomes: A population-based investigation. Pharmacoepidemiology and drug safety. 2017;26(9):1100-8.

56.   Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. Jama. 2013;309(16):1696-703.

57.   Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiology and drug safety. 2007;16(10):1086-94.

58.   Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect. CNS drugs. 2008;22(4):325-34.

59.   El Marroun H, White TJ, van der Knaap NJ, Homberg JR, Fernandez G, Schoemaker NK, et al. Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children. The British journal of psychiatry : the journal of mental science. 2014;205(2):95-102.

60.   Eroglu E, Gokcil Z, Bek S, Ulas UH, Odabasi Z. Pregnancy and teratogenicity of antiepileptic drugs. Acta neurologica Belgica. 2008;108(2):53-7.

61.   Figueroa R. Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. Journal of developmental and behavioral pediatrics : JDBP. 2010;31(8):641-8.

62.   Fonager K, Larsen H, Pedersen L, Sorensen HT. Birth outcomes in women exposed to anticonvulsant drugs. Acta neurologica Scandinavica. 2000;101(5):289-94.

63.   Gladstone DJ, Bologa M, Maguire C, Pastuszak A, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive toxicology (Elmsford, NY). 1992;6(3):257-61.

64.   Guveli BT, Rosti RO, Guzeltas A, Tuna EB, Atakli D, Sencer S, et al. Teratogenicity of Antiepileptic Drugs. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2017;15(1):19-27.

65.   Hernandez-Diaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692-9.

66.   Hirano T, Fujioka K, Okada M, Iwasa H, Kaneko S. Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia. 2004;45 Suppl 8:53-7.

67.   Holmes LB, Harvey EA, Brown KS, Hayes AM, Khoshbin S. Anticonvulsant teratogenesis: I. A study design for newborn infants. Teratology. 1994;49(3):202-7.

68.   Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2008;71(4):272-6.

69.   Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. The New England journal of medicine. 2013;369(25):2406-15.

70.   Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology. 2003;60(4):575-9.

71.   Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Archives of pediatrics & adolescent medicine. 2004;158(4):312-6.

72.   Kallen B, Reis M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. Journal of clinical psychopharmacology. 2012;32(5):608-14.

73.   Kaneko S, Otani K, Fukushima Y, Ogawa Y, Nomura Y, Ono T, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia. 1988;29(4):459-67.

74.   Kaneko S, Otani K, Kondo T, Fukushima Y, Nakamura Y, Ogawa Y, et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology. 1992;42(4 Suppl 5):68-74.

75.   Katz JM, Pacia SV, Devinsky O. Current Management of Epilepsy and Pregnancy: Fetal Outcome, Congenital Malformations, and Developmental Delay. Epilepsy & behavior : E&B. 2001;2(2):119-23.

76.   Kelly TE, Edwards P, Rein M, Miller JQ, Dreifuss FE. Teratogenicity of anticonvulsant drugs. II: A prospective study. American journal of medical genetics. 1984;19(3):435-43.

77.   King PB, Lie RT, Irgens LM. Spina bifida and cleft lip among newborns of Norwegian women with epilepsy: changes related to the use of anticonvulsants. American journal of public health. 1996;86(10):1454-6.

78.   Knickmeyer RC, Meltzer-Brody S, Woolson S, Hamer RM, Smith JK, Lury K, et al. Rate of Chiari I malformation in children of mothers with depression with and without prenatal SSRI exposure. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2014;39(11):2611-21.

79.   Koch S, Jager-Roman E, Losche G, Nau H, Rating D, Helge H. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta paediatrica (Oslo, Norway : 1992). 1996;85(6):739-46.

80.   Koch S, Losche G, Jager-Roman E, Jakob S, Rating D, Deichl A, et al. Major and minor birth malformations and antiepileptic drugs. Neurology. 1992;42(4 Suppl 5):83-8.

81.   Koch S, Titze K, Zimmermann RB, Schroder M, Lehmkuhl U, Rauh H. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia. 1999;40(9):1237-43.

82.   Kulaga S, Sheehy O, Zargarzadeh AH, Moussally K, Berard A. Antiepileptic drug use during pregnancy: perinatal outcomes. Seizure. 2011;20(9):667-72.

83.   Laugesen K, Olsen MS, Telen Andersen AB, Froslev T, Sorensen HT. In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder: a nationwide Danish cohort study. BMJ open. 2013;3(9):e003507.

84.   Leibovitch L, Rymer-Haskel N, Schushan-Eisen I, Kuint J, Strauss T, Maayan-Metzger A. Short-term neonatal outcome among term infants after in utero exposure to serotonin reuptake inhibitors. Neonatology. 2013;104(1):65-70.

85.   Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. Journal of clinical psychopharmacology. 2007;27(6):607-13.

86.   Lin AE, Peller AJ, Westgate MN, Houde K, Franz A, Holmes LB. Clonazepam use in pregnancy and the risk of malformations. Birth defects research Part A, Clinical and molecular teratology. 2004;70(8):534-6.

87.   Losche G, Steinhausen HC, Koch S, Helge H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta paediatrica (Oslo, Norway : 1992). 1994;83(9):961-6.

88.   Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstetrics and gynecology. 2011;118(1):111-20.

89.   Malm H, Brown AS, Gissler M, Gyllenberg D, Hinkka-Yli-Salomaki S, McKeague IW, et al. Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study. Journal of the American Academy of Child and Adolescent Psychiatry. 2016;55(5):359-66.

90.   Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, et al. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ (Clinical research ed). 2017;357:j2350.

91.   Mawer G, Briggs M, Baker GA, Bromley R, Coyle H, Eatock J, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure. 2010;19(2):112-9.

92.   Mawer G, Clayton-Smith J, Coyle H, Kini U. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure. 2002;11(8):512-8.

93.   Mawhinney E, Campbell J, Craig J, Russell A, Smithson W, Parsons L, et al. Valproate and the risk for congenital malformations: Is formulation and dosage regime important? Seizure. 2012;21(3):215-8.

94.   Mawhinney E, Craig J, Morrow J, Russell A, Smithson WH, Parsons L, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology. 2013;80(4):400-5.

95.   Nakane Y, Okuma T, Takahashi R, Sato Y, Wada T, Sato T, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia. 1980;21(6):663-80.

96.   Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American journal of medical genetics. 1997;68(1):18-24.

97.   Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology. 1992;42(4 Suppl 5):119-25.

98.   Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of disease in childhood. 1996;75(6):517-20.

99.   Ozdemir O, Sari ME, Kurt A, Sakar VS, Atalay CR. Pregnancy outcome of 149 pregnancies in women with epilepsy: Experience from a tertiary care hospital. Interventional medicine & applied science. 2015;7(3):108-13.

100.   Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). Jama. 1993;269(17):2246-8.

101.   Rai D, Lee BK, Dalman C, Newschaffer C, Lewis G, Magnusson C. Antidepressants during pregnancy and autism in offspring: population based cohort study. BMJ (Clinical research ed). 2017;358:j2811.

102.   Richmond JR, Krishnamoorthy P, Andermann E, Benjamin A. Epilepsy and pregnancy: an obstetric perspective. American journal of obstetrics and gynecology. 2004;190(2):371-9.

103.   Samren EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Annals of neurology. 1999;46(5):739-46.

104.   Sawhney H, Vasishta K, Suri V, Khunnu B, Goel P, Sawhney IM. Pregnancy with epilepsy--a retrospective analysis. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 1996;54(1):17-22.

105.   Sorensen MJ, Gronborg TK, Christensen J, Parner ET, Vestergaard M, Schendel D, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clinical epidemiology. 2013;5:449-59.

106.   Sujan AC, Rickert ME, Oberg AS, Quinn PD, Hernandez-Diaz S, Almqvist C, et al. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. Jama. 2017;317(15):1553-62.

107.   Tanganelli P, Regesta G. Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology. 1992;42(4 Suppl 5):89-93.

108.   Thomas SV, Indrani L, Devi GC, Jacob S, Beegum J, Jacob PP, et al. Pregnancy in women with epilepsy : preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India. 2001;49(1):60-6.

109.   Thomas SV, Sukumaran S, Lukose N, George A, Sarma PS. Intellectual and language functions in children of mothers with epilepsy. Epilepsia. 2007;48(12):2234-40.

110.   Titze K, Koch S, Helge H, Lehmkuhl U, Rauh H, Steinhausen HC. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental medicine and child neurology. 2008;50(2):117-22.

111.   Vajda FJ, Graham JE, Hitchcock AA, O'Brien TJ, Lander CM, Eadie MJ. Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure. 2010;19(9):558-61.

112.   Vajda FJ, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. The Australian & New Zealand journal of obstetrics & gynaecology. 2007;47(6):468-74.

113.   Vajda FJ, O'Brien TJ, Graham J, Lander CM, Eadie MJ. Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta neurologica Scandinavica. 2013;128(4):228-34.

114.   Vajda FJ, O'Brien TJ, Graham JE, Lander CM, Eadie MJ. Dose dependence of fetal malformations associated with valproate. Neurology. 2013;81(11):999-1003.

115.   Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2003;10(5):543-9.

116.   van der Pol MC, Hadders-Algra M, Huisjes HJ, Touwen BC. Antiepileptic medication in pregnancy: late effects on the children's central nervous system development. American journal of obstetrics and gynecology. 1991;164(1 Pt 1):121-8.

117.   Vanya M, Arva-Nagy N, Szili K, Szok D, Bartfai G. EFFECTS OF MATERNAL EPILEPSY AND ANTIEPILEPTIC THERAPY IN WOMEN DURING PREGNANCY. Ideggyogyaszati szemle. 2015;68(3-4):105-12.

118.   Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia. 2009;50(9):2130-9.

119.   Videman M, Stjerna S, Roivainen R, Nybo T, Vanhatalo S, Gaily E, et al. Evidence for spared attention to faces in 7-month-old infants after prenatal exposure to antiepileptic drugs. Epilepsy & behavior : E&B. 2016;64(Pt A):62-8.

120.   Viinikainen K, Heinonen S, Eriksson K, Kalviainen R. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia. 2006;47(1):186-92.

121.   Viktorin A, Uher R, Kolevzon A, Reichenberg A, Levine SZ, Sandin S. Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring. JAMA psychiatry. 2017;74(10):1031-8.

122.   Viktorin A, Uher R, Reichenberg A, Levine SZ, Sandin S. Autism risk following antidepressant medication during pregnancy. Psychological medicine. 2017:1-10.

123.   Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker GA. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology. 2005;64(6):949-54.

124.   Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. American journal of obstetrics and gynecology. 2006;194(4):961-6.

125.   Wide K, Winbladh B, Tomson T, Sars-Zimmer K, Berggren E. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental medicine and child neurology. 2000;42(2):87-92.

126.   Winterfeld U, Merlob P, Baud D, Rousson V, Panchaud A, Rothuizen LE, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology. 2016;86(24):2251-7.

127.   Wood AG, Nadebaum C, Anderson V, Reutens D, Barton S, O'Brien TJ, et al. Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy. Epilepsia. 2015;56(7):1047-55.

128.   Petersen I, McCrea RL, Sammon CJ, Osborn DP, Evans SJ, Cowen PJ, et al. Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. Health technology assessment (Winchester, England). 2016;20(23):1-176.

129.   Li B, Quan H, Fong A, Lu M. Assessing record linkage between health care and Vital Statistics databases using deterministic methods. BMC health services research. 2006;6(1):48.

130.   Herman A, McCarthy B, Bakewell J, Ward R, Mueller B, Maconochie N, et al. Data linkage methods used in maternally‐linked birth and infant death surveillance data sets from the United States (Georgia, Missouri, Utah and Washington State), Israel, Norway, Scotland and Western Australia. Paediatric and perinatal epidemiology. 1997;11(S1):5-22.

131.   Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383-8.

132.   Arnold BF, Ercumen A, Benjamin-Chung J, Colford Jr JM. Brief report: negative controls to detect selection bias and measurement bias in epidemiologic studies. Epidemiology (Cambridge, Mass). 2016;27(5):637.

133.   Group ES. Seizure control and treatment in pregnancy Observations from the EURAP Epilepsy Pregnancy Registry. Neurology. 2006;66(3):354-60.

134.   Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery & Psychiatry. 2006;77(2):193-8.

135.	MacDonald SC, Bateman BT, McElrath TF, Hernández-Díaz S. Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States. JAMA neurology. 2015;72(9):981-8.

136.	Lao KS, Tam AW, Wong IC, Besag F, Man KK, Chui CS, et al. Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: General and vulnerable patient groups. Pharmacoepidemiology and drug safety. 2017;26(11):1387-94.

137.	Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, Dublin S, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the US, 2001–2007: a population-based study of 585,615 deliveries. Archives of women's mental health. 2013;16(2):149-57.

138.	Gliklich RE DN, Leavy MB, editors. . Registries for Evaluating Patient Outcomes: A User's Guide [Internet]. 3rd edition.: Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Apr.

139.	Christensen J, Vestergaard M, Olsen J, Sidenius P. Validation of epilepsy diagnoses in the Danish National Hospital Register. Epilepsy research. 2007;75(2-3):162-70.

140.	Quan H, Li B, Saunders LD, Parsons GA, Nilsson CI, Alibhai A, et al. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health services research. 2008;43(4):1424-41.

141.	Bock C, Bukh JD, Vinberg M, Gether U, Kessing LV. Validity of the diagnosis of a single depressive episode in a case register. Clinical practice and epidemiology in mental health : CP & EMH. 2009;5:4.

142.	Jette N, Reid AY, Quan H, Hill MD, Wiebe S. How accurate is ICD coding for epilepsy? Epilepsia. 2010;51(1):62-9.

143.	Idring S, Rai D, Dal H, Dalman C, Sturm H, Zander E, et al. Autism spectrum disorders in the Stockholm Youth Cohort: design, prevalence and validity. PloS one. 2012;7(7):e41280.

144.	Larsson H, Ryden E, Boman M, Langstrom N, Lichtenstein P, Landen M. Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. The British journal of psychiatry : the journal of mental science. 2013;203(2):103-6.

145.	Lundstrom S, Reichenberg A, Anckarsater H, Lichtenstein P, Gillberg C. Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general population samples. BMJ (Clinical research ed). 2015;350:h1961.

146.	Nathan H, Pawlik TM. Limitations of claims and registry data in surgical oncology research. Annals of Surgical Oncology. 2008;15(2):415-23.

147.	Kirkwood BR, Sterne JA. Essential medical statistics: John Wiley & Sons; 2010.

148.	Blair A, Stewart P, Lubin JH, Forastiere F. Methodological issues regarding confounding and exposure misclassification in epidemiological studies of occupational exposures. American journal of industrial medicine. 2007;50(3):199-207.

149.	Ahrens W, Pigeot I. Handbook of epidemiology: Springer; 2014.

150.	Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. American journal of epidemiology. 1977;105(5):488-95.

151.	Blakely T, Salmond C. Probabilistic record linkage and a method to calculate the positive predictive value. International journal of epidemiology. 2002;31(6):1246-52.

152.	Zhu Y, Chen CY, Matsuyama Y, Ohashi Y, Franklin JM, Setoguchi S. Comparative validity of methods to select appropriate cutoff weight for probabilistic linkage without unique personal identifiers. Pharmacoepidemiology and drug safety. 2016;25(4):444-52.

153.	Setoguchi S, Zhu Y, Jalbert JJ, Williams LA, Chen CY. Validity of deterministic record linkage using multiple indirect personal identifiers: linking a large registry to claims data. Circulation Cardiovascular quality and outcomes. 2014;7(3):475-80.

154.	Swart A, Meagher NS, van Leeuwen MT, Zhao K, Grulich A, Mao L, et al. Examining the quality of name code record linkage: what is the impact on death and cancer risk estimates? A validation study. Australian and New Zealand journal of public health. 2015;39(2):141-7.

155.   Bandoli G, Palmsten K, Flores KF, Chambers CD. Constructing causal diagrams for common perinatal outcomes: benefits, limitations and motivating examples with maternal antidepressant use in pregnancy. Paediatric and perinatal epidemiology. 2016;30(5):521-8.

156.   d'Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in medicine. 1998;17(19):2265-81.

157.   Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, et al. Antidepressant use in pregnancy and the risk of cardiac defects. New England Journal of Medicine. 2014;370(25):2397-407.

158.   Salas M, Hotman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. American journal of epidemiology. 1999;149(11):981-3.

159.   Donovan SJ, Susser E. Commentary: Advent of sibling designs. International journal of epidemiology. 2011;40(2):345-9.

160.   Frisell T, Öberg S, Kuja-Halkola R, Sjölander A. Sibling comparison designs: bias from non-shared confounders and measurement error. Epidemiology. 2012;23(5):713-20.

161.   Cheslack-Postava K, Liu K, Bearman PS. Closely spaced pregnancies are associated with increased odds of autism in California sibling births. Pediatrics. 2011;127(2):246-53.

162.   Brew BK, Gong T, Williams DM, Larsson H, Almqvist C. Using fathers as a negative control exposure to test the Developmental Origins of Health and Disease Hypothesis: A case study on maternal distress and offspring asthma using Swedish register data. Scandinavian journal of public health. 2017;45(17_suppl):36-40.

163.   Lupattelli A, Spigset O, Björnsdóttir I, Hämeen‐Anttila K, Mårdby AC, Panchaud A, et al. PATTERNS AND FACTORS ASSOCIATED WITH LOW ADHERENCE TO PSYCHOTROPIC MEDICATIONS DURING PREGNANCY—A CROSS‐SECTIONAL, MULTINATIONAL WEB‐BASED STUDY. Depression and anxiety. 2015;32(6):426-36.

164.   Harris G-ME, Wood M, Eberhard-Gran M, Lundqvist C, Nordeng H. Patterns and predictors of analgesic use in pregnancy: a longitudinal drug utilization study with special focus on women with migraine. BMC pregnancy and childbirth. 2017;17(1):224.

165.   Lactation. IoMUCoNSDPa. Nutrition During Pregnancy: Part I Weight Gain: Part II Nutrient Supplements.: Washington (DC): National Academies Press (US); 1990.